Posted by Michael Wonder on 24 Aug 2022
FDA approves ibrutinib for paediatric patients with chronic graft versus host disease, including a new oral suspension
24 August 2022 - Today, the FDA approved ibrutinib (Imbruvica, Pharmacyclics) for paediatric patients ≥ 1 year of age with chronic graft versus host disease after failure of 1 or more lines of systemic therapy.
Formulations include capsules, tablets, and oral suspension.
